12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lyxumia lixisenatide: Additional Phase III data

Additional data from the double-blind, international Phase III GetGoal-L trial in 495 Type II diabetics inadequately controlled with basal insulin showed that once-daily 20 µg Lyxumia as an add-on to basal insulin with or without metformin significantly reduced HbA1c from baseline to week 24, the primary endpoint, by 0.74% vs. 0.38% for placebo (p=0.0002). Lyxumia also led to significant mean reductions in body weight (1.8 vs. 0.52...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >